What is the treatment for hypothyroidism with a Thyroid-Stimulating Hormone (TSH) level of 9 and a C-Reactive Protein (CRP) level of 3?

Treatment of Hypothyroidism with TSH 9 and CRP 3

Initiate levothyroxine therapy immediately for this patient with TSH of 9 mIU/L, as this level approaches the threshold where treatment is strongly recommended regardless of symptoms. 1

Confirming the Diagnosis Before Treatment

• Confirm the elevated TSH with repeat testing after 3-6 weeks, as 30-60% of elevated TSH levels normalize spontaneously on repeat measurement. 1, 2
• Measure both TSH and free T4 to distinguish between subclinical hypothyroidism (normal free T4) and overt hypothyroidism (low free T4). 1
• The CRP level of 3 mg/L is mildly elevated but does not contraindicate thyroid hormone replacement; however, rule out acute illness that could transiently affect TSH levels. 1

Treatment Decision Algorithm

For TSH = 9 mIU/L specifically:

• This level sits in a gray zone where treatment recommendations vary, but treatment is reasonable and increasingly recommended based on recent evidence showing the median TSH at which levothyroxine is initiated has decreased from 8.7 to 7.9 mIU/L. 1
• Treatment becomes mandatory at TSH >10 mIU/L regardless of symptoms, as this carries approximately 5% annual risk of progression to overt hypothyroidism. 1, 3
• At TSH = 9 mIU/L, strongly consider treatment if the patient has any of the following: symptoms (fatigue, weight gain, cold intolerance, constipation), positive anti-TPO antibodies (4.3% vs 2.6% annual progression risk), goiter, infertility, or is planning pregnancy. 1, 3, 4

Levothyroxine Dosing Strategy

Initial dosing depends on age and cardiac status:

• For patients <70 years without cardiac disease: Start with full replacement dose of approximately 1.6 mcg/kg/day taken on an empty stomach. 1
• For patients >70 years or with cardiac disease/multiple comorbidities: Start with lower dose of 25-50 mcg/day and titrate gradually to avoid cardiac complications. 1, 5
• The goal is to normalize TSH to the reference range (0.5-4.5 mIU/L), with optimal target of 0.5-2.0 mIU/L. 3

Monitoring Protocol

• Recheck TSH and free T4 in 6-8 weeks after initiating therapy to evaluate response, as levothyroxine has a long half-life requiring this interval to reach steady state. 1, 5
• Adjust dose in increments of 12.5-25 mcg based on TSH response. 1
• Once TSH is normalized, monitor every 6-12 months or sooner if symptoms change. 1

Critical Pitfalls to Avoid

• Do not treat based on a single elevated TSH value without confirmation testing, as transient elevations are common. 1, 2
• Avoid overtreatment, which occurs in 14-21% of patients and increases risk for atrial fibrillation, osteoporosis, fractures, and cardiovascular mortality, especially in elderly patients. 1, 5
• Never start levothyroxine before ruling out adrenal insufficiency in patients with suspected central hypothyroidism, as this can precipitate adrenal crisis. 1, 6
• Be aware of drug interactions: Iron, calcium, proton pump inhibitors, and antacids reduce levothyroxine absorption and should be separated by at least 4 hours. 6
• Approximately 25% of patients on levothyroxine are unintentionally maintained on doses sufficient to fully suppress TSH, highlighting the importance of regular monitoring. 1

Special Considerations

• If the patient is female and planning pregnancy, treatment is mandatory at any TSH elevation, as subclinical hypothyroidism is associated with preeclampsia, low birth weight, and potential neurodevelopmental effects in offspring. 1, 4
• Check anti-TPO antibodies if not already done, as positive antibodies indicate autoimmune etiology with higher progression risk (4.3% vs 2.6% per year) and strengthen the case for treatment. 1, 3
• Recent evidence shows mortality increases when TSH is outside the normal range in treated patients, supporting aggressive normalization of TSH levels. 7